-$0.40 EPS Expected for Jounce Therapeutics, Inc. (NASDAQ:JNCE) This Quarter

Wall Street brokerages expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to post earnings of ($0.40) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Jounce Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.02). Jounce Therapeutics reported earnings of ($0.73) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 45.2%. The firm is scheduled to report its next earnings results on Friday, November 5th.

According to Zacks, analysts expect that Jounce Therapeutics will report full year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.87) to ($0.65). For the next financial year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.64) to ($0.68). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Thursday, August 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.28. The business had revenue of $25.37 million during the quarter, compared to analysts’ expectations of $9.48 million.

A number of research firms recently commented on JNCE. Raymond James raised shares of Jounce Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Tuesday, September 14th. Piper Sandler decreased their target price on shares of Jounce Therapeutics from $20.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, August 5th. Finally, Zacks Investment Research cut shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 7th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Jounce Therapeutics presently has an average rating of “Buy” and an average price target of $12.55.

NASDAQ:JNCE opened at $8.36 on Monday. Jounce Therapeutics has a 52 week low of $5.03 and a 52 week high of $14.84. The firm has a 50 day moving average of $6.75 and a 200 day moving average of $7.35. The stock has a market capitalization of $428.30 million, a price-to-earnings ratio of -15.77 and a beta of 0.97.

A number of institutional investors have recently modified their holdings of the business. Citigroup Inc. increased its stake in shares of Jounce Therapeutics by 132.5% in the second quarter. Citigroup Inc. now owns 4,673 shares of the company’s stock worth $32,000 after acquiring an additional 2,663 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Jounce Therapeutics in the first quarter worth $56,000. MML Investors Services LLC acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $68,000. Invesco Ltd. acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $76,000. Finally, Hancock Whitney Corp acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $79,000. Institutional investors and hedge funds own 69.00% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.

Featured Story: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.